The Intermountain Risk Score, based on common laboratory tests, was highly predictive of short-term mortality

2009 ◽  
Vol 14 (6) ◽  
pp. 186-186
Author(s):  
B. E Johnson
2017 ◽  
Vol 38 (suppl_1) ◽  
Author(s):  
I. Battistoni ◽  
M. Marini ◽  
J.A. Borovac ◽  
M. Francioni ◽  
C. Sorini Dini ◽  
...  

2019 ◽  
Vol 40 (32) ◽  
pp. 2684-2694 ◽  
Author(s):  
Ferran Rueda ◽  
Eva Borràs ◽  
Cosme García-García ◽  
Oriol Iborra-Egea ◽  
Elena Revuelta-López ◽  
...  

Abstract Aims Cardiogenic shock (CS) is associated with high short-term mortality and a precise CS risk stratification could guide interventions to improve patient outcome. Here, we developed a circulating protein-based score to predict short-term mortality risk among patients with CS. Methods and results Mass spectrometry analysis of 2654 proteins was used for screening in the Barcelona discovery cohort (n = 48). Targeted quantitative proteomics analyses (n = 51 proteins) were used in the independent CardShock cohort (n = 97) to derive and cross-validate the protein classifier. The combination of four circulating proteins (Cardiogenic Shock 4 proteins—CS4P), discriminated patients with low and high 90-day risk of mortality. CS4P comprises the abundances of liver-type fatty acid-binding protein, beta-2-microglobulin, fructose-bisphosphate aldolase B, and SerpinG1. Within the CardShock cohort used for internal validation, the C-statistic was 0.78 for the CardShock risk score, 0.83 for the CS4P model, and 0.84 (P = 0.033 vs. CardShock risk score) for the combination of CardShock risk score with the CS4P model. The CardShock risk score with the CS4P model showed a marked benefit in patient reclassification, with a net reclassification improvement (NRI) of 0.49 (P = 0.020) compared with CardShock risk score. Similar reclassification metrics were observed in the IABP-SHOCK II risk score combined with CS4P (NRI =0.57; P = 0.032). The CS4P patient classification power was confirmed by enzyme-linked immunosorbent assay (ELISA). Conclusion A new protein-based CS patient classifier, the CS4P, was developed for short-term mortality risk stratification. CS4P improved predictive metrics in combination with contemporary risk scores, which may guide clinicians in selecting patients for advanced therapies.


2009 ◽  
Vol 11 (4) ◽  
pp. 236-242 ◽  
Author(s):  
Ana Teresa Timóteo ◽  
Alexandra Toste ◽  
Ruben Ramos ◽  
Fernando Miranda ◽  
Maria Lurdes Ferreira ◽  
...  

Author(s):  
Robert G Zoble ◽  
Erin E Fowler ◽  
Jonathan Meadows ◽  
Adam Zoble ◽  
Philip Foulis ◽  
...  

Background: Heart failure (HF) has a high rate of mortality. It would be useful to have, at the time of a HF admission, a method of predicting post-discharge short-term mortality risk. Methods: We studied 947 Veterans hospitalized for HF at our VA medical center from January 2004 to December 2008, survived to discharge, had an ICD-9 code for HF as the primary discharge diagnosis, and had complete data for comorbidities, labs, medications and ECG findings. Mortality at 30-days post-discharge was determined and multivariable analyses identified independent predictors of mortality by logistic regression. These were used to develop a mortality risk score. Results: Mortality at 30-days occurred in 3.9% (37/947). Independent predictors (p-value <0.05) were substance abuse (OR = 3.10), abnormal admission serum sodium (OR=2.56), abnormal admission troponin (OR = 2.15), absence of dyslipidemia (OR = 2.04), not on a calcium channel blocker at admission (OR = 3.33), and not on an oral anticoagulant at admission (OR = 5.26). Each independent predictor was assigned 1-point and the resulting figure shows the rates of 30-day mortality to be 0.49%, 5.33% and 19.15% for those with risk scores of 0 to 2, 3 or 4, and ≥5, respectively. This represents a 39-fold difference in risk between the low-risk and high-risk patients. The c-statistic for the model was good (c = 0.796). Conclusions: Risk for post-discharge short-term mortality can be accurately predicted at the time of initial HF admission by a risk score employing admission labs, co-morbidities and medications. Patients identified as high risk at the time of admission might benefit from more intense inpatient evaluation and closer outpatient care.


2020 ◽  
Vol 77 ◽  
pp. 52-58
Author(s):  
Susana García-Gutiérrez ◽  
Ane Antón-Ladislao ◽  
Raul Quiros ◽  
Antonio Lara ◽  
Irene Rilo ◽  
...  

1981 ◽  
Vol 46 (04) ◽  
pp. 752-756 ◽  
Author(s):  
L Zuckerman ◽  
E Cohen ◽  
J P Vagher ◽  
E Woodward ◽  
J A Caprini

SummaryThrombelastography, although proven as a useful research tool has not been evaluated for its clinical utility against common coagulation laboratory tests. In this study we compare the thrombelastographic measurements with six common tests (the hematocrit, platelet count, fibrinogen, prothrombin time, activated thromboplastin time and fibrin split products). For such comparisons, two samples of subjects were selected, 141 normal volunteers and 121 patients with cancer. The data was subjected to various statistical techniques such as correlation, ANOVA, canonical and discriminant analysis to measure the extent of the correlations between the two sets of variables and their relative strength to detect blood clotting abnormalities. The results indicate that, although there is a strong relationship between the thrombelastographic variables and these common laboratory tests, the thrombelastographic variables contain additional information on the hemostatic process.


Sign in / Sign up

Export Citation Format

Share Document